These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10522982

  • 1. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA.
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [Abstract] [Full Text] [Related]

  • 2. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP, Legros JJ, Rollet J, Augès M, Bunouf P, Sournac M, Fiet J.
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [Abstract] [Full Text] [Related]

  • 5. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.
    Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA.
    Urology; 1997 Feb; 49(2):191-6. PubMed ID: 9037280
    [Abstract] [Full Text] [Related]

  • 6. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
    Dobs AS, Bachorik PS, Arver S, Meikle AW, Sanders SW, Caramelli KE, Mazer NA.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA.
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [Abstract] [Full Text] [Related]

  • 8. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 May; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 9. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [Abstract] [Full Text] [Related]

  • 10. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 11. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N.
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 13. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester.
    Behre HM, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1204-10. PubMed ID: 1430080
    [Abstract] [Full Text] [Related]

  • 14. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N, Testosterone Gel Study Group.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [Abstract] [Full Text] [Related]

  • 15. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [Abstract] [Full Text] [Related]

  • 17. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S, Nieschlag E.
    J Androl; 2002 Mar; 23(3):419-25. PubMed ID: 12002444
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
    Dobs AS, Hoover DR, Chen MC, Allen R.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C, Harnett M, Dobs AS, Swerdloff RS.
    J Androl; 2010 Jan; 31(5):457-65. PubMed ID: 20133964
    [Abstract] [Full Text] [Related]

  • 20. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS.
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.